CD47 and Thrombocytopenia: It is anticipated that using anti-SIRPα to target the SIRPα/CD47 axis may have a beneficial safety profile due to SIRPα’s more constrained expression, which can lower the risk of adverse events such as acute anemia, thrombocytopenia caused by anti-CD47 [105].